NY-LIME-TRADNG/TKEPROFIT
Lime Trading Corp (“Lime Trading”), a tech-first agency broker headquartered in New York City, proudly announces its strategic partnership with west coast start up TakeProfit, a pioneering community-driven trader platform based in San Francisco, California. This collaboration was born from a joint belief that traders should have access to the best tools and technology no matter their strategy. This new partnership offers retail traders access to the newest innovations in charting and technical analysis, coupled with Lime Trading's industry-leading trade execution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502144682/en/
The newly launched TakeProfit trading platform now offers widgets that integrate seamlessly with Lime Trading. Lime clients will be able to now place trades from the TakeProfit platform and view their portfolio all in one place. (Graphic: Business Wire)
Lime Trading is the only broker connected to TakeProfit, offering exclusive access to a trading widget native to the TakeProfit platform. Now traders can ideate and trade in one, seamless experience without ever leaving the platform. “We are thrilled to introduce this integration with TakeProfit,” remarked Johan Sandblom, CEO at Lime Trading. “By merging Lime Trading's expertise in trade execution with TakeProfit's innovative platform, we are equipping retail traders with the essential tools needed to help navigate today's dynamic markets efficiently.”
Alexey Shulzhenko, TakeProfit’s Founder & CEO said, “We partnered with Lime because they have a passion to build the best for traders, by traders. Their focus on providing all traders with lower latency technology aligns with our mission to bring traders the tools they need to trade more effectively.”
This partnership is just one of a few, recent product enhancements that Lime Trading has released to enhance their retail offering. Most recently they’ve added a Python SDK for their REST API and streamlined their demo paper trading access for traders to test drive Lime for themselves.
Traders wanting to try the TakeProfit trade integration that do not yet have a Lime account to experience this new integration, are able to sign up for a free demo paper account. For more information regarding Lime Trading and TakeProfit's new partnership, visit m.lime.co/takeprofit.
About Lime Trading
For over twenty years, Lime Trading has been focused on developing tools and technology to enhance traders’ access to markets. Focused on lower latency execution, Lime Trading works with retail and institutional clients alike to offer a broad range of APIs, platforms, and technology solutions to traders worldwide. Lime Trading Corp is an SEC-registered broker-dealer, member of FINRA/SIPC/NFA. For more information, visit Lime.co.
About TakeProfit
TakeProfit is a community-driven trading platform equipped with monetization tools for traders. It facilitates sharing research and making better trading decisions, allowing members to capitalize on their expertise. Workspaces are created using widgets, providing a customizable trading environment with immersive charting, custom indicators, screeners, financials, and other tools. TakeProfit brings desktop functionality to the web, utilizing new browser technologies and leveraging the advantages of cloud products. Learn more about TakeProfit at TakeProfit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502144682/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom